Who
Bridget A. Martell
Director
Company insider
Files Form 4 as: Director, Aligos Therapeutics; Director, Delcath Systems; Director, Achieve Life Sciences; Director, POINT Biopharma Global; Acting Chief Medical Officer, Kura Oncology; Chief Medical Officer, Juniper Pharmaceuticals.
In numbers
- Trades disclosed
- 25
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 6
- Companies where not an officer
- 4
- First trade
- 6 Jan 2015
- Last trade
- 25 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Jun 2026filed 29 Jun 2026 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,860 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,860 at $0.00 | filing |
| 13 May 2026filed 14 May 2026 | DCTH Delcath Systemsoption or derivative · Medical Devices | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 13 May 2026filed 14 May 2026 | DCTH Delcath Systemsoption or derivative · Medical Devices | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 25 Jun 2025filed 26 Jun 2025 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,860 at $0.00 | filing |
| 6 Jun 2025filed 10 Jun 2025 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —31,500 at $0.00 | filing |
| 15 May 2025filed 19 May 2025 | DCTH Delcath Systemsoption or derivative · Medical Devices | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 27 Jun 2024filed 28 Jun 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 23 May 2024filed 28 May 2024 | DCTH Delcath Systemsoption or derivative · Medical Devices | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 28 Feb 2024filed 28 Feb 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,823 at $0.00 | filing |
| 27 Feb 2024filed 28 Feb 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —30,000 at $0.00 | filing |
| 22 Jan 2024filed 29 Jan 2024 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —31,500 at $0.00 | filing |
| 20 Jul 2023filed 21 Jul 2023 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 13 Jun 2023filed 14 Jun 2023 | POINT Biopharma Globaloption or derivative | SEC FORM 4 Code A | —80,503 at $0.00 | filing |
| 7 Jun 2023filed 9 Jun 2023 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —31,500 at $0.00 | filing |
| 23 Jun 2022filed 27 Jun 2022 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 31 May 2022filed 1 Jun 2022 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —4,400 at $0.00 | filing |
| 16 Nov 2021filed 18 Nov 2021 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 15 Mar 2021filed 17 Mar 2021 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —5,650 at $0.00 | filing |
| 10 Feb 2020filed 12 Feb 2020 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.